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Summary
 
The B lymphocyte–induced maturation protein (Blimp-1) upregulates the expression of synde-
can-1 and J chain and represses that of c-myc. We have transfected Blimp-1 into two sublines
of the BCL1 B cell lymphoma that represent distinct stages of B cell development in secondary
lymphoid tissues. After interleukin (IL)-2 and IL-5 stimulation, the BCL1 3B3 cells differenti-
ate into centrocyte-like cells, whereas the BCL1 5B1b cells blast and appear to be blocked at
the centroblast stage. This blasting effect and the increase in IgM secretion that follows it can
be blocked by a dominant negative form of Blimp-1. At the same time, the ectopic expression
of Blimp-1 in these partially activated cells induces an apoptotic response that also can be sup-
pressed by the same dominant negative protein. A similar effect was noticed when Blimp-1 was
expressed in the mature L10A and the immature WEHI-231 lines, indicating this may be a
general effect at earlier stages of the B cell development, and distinct from the ability of Blimp-1
to induce maturation in late stages of differentiation. Truncation mutants indicate that the in-
duction of the apoptotic response relies mainly on 69 amino acids within Blimp-1’s proline-
rich domain. We propose that Blimp-1 expression defines a checkpoint beyond which fully
activated B cells proceed to the plasma cell stage, whereas immature and partially activated cells
are eliminated at this point.
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D
 
ifferentiation of B lymphocytes into plasma cells de-
pends on their continuous exposure to prodifferentia-
tion and antiapoptosis signals. The majority of nonreactive
and self-reactive clones are eliminated in the bone marrow
at the pro– (1, 2) and pre–B stages (3). Once mature, the
recruitment of new B cells to the long-lived recirculating B
cell pool depends on a positive selection process that takes
place in the splenic periarteriolar lymphoid sheath (PALS;
reference 4). Upon antigen encounter, these long-lived cir-
culating cells are retained in secondary lymphoid organs.
After being exposed to the appropriate T cell help, they
proliferate and relocate to germinal centers (5), where they
are subjected to negative selection before the onset of so-
matic mutation (6). The surviving cells interact with follic-
ular dendritic cells that supply proliferative, antiapoptotic
signals (7, 8) and upregulate the expression of multiple re-
ceptors required for T cell interaction (9, 10). The selected
B cell clones then interact with T cells that provide them
with additional survival signals, induce isotype switching
(11, 12), and aid in their differentiation into plasma or
memory cells. Transcription factors that regulate the sur-
vival of developing B cells at different points along this
pathway remain largely unknown.
We have previously shown that IL-2 and IL-5 upregu-
late the expression of the B lymphocyte–induced matura-
tion protein (Blimp-1)
 
1
 
 in mature B cells (13). Blimp-1 and
its human homologue PRDI-BF1 (14, 15) are zinc finger
proteins that contain four Kruppel-like zinc fingers as well
as a number of other domains that may mediate protein–
protein interactions (13, 16). Transfection of Blimp-1 into
the BCL1 CW13.20-3B3 mature B cell line (hereafter re-
ferred to as 3B3) induces IgM secretion, J chain upregula-
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); afU, arbitrary fluores-
cence units; Blimp, B lymphocyte–induced maturation protein; FLAG,
flu antigen; GFP, green fluorescent protein; NLS, nuclear localization sig-
nal(s); ORF, open reading frame; PI, propidium iodide; PR, PRD1-BF1-
RIZ homology; TUNEL, TdT-mediated dUTP nick end labeling.
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tion, and Syndecan-1 expression (13). Blimp-1 has also been
shown recently to regulate the expression of c-myc in ma-
ture B cells (17). As Blimp-1 is gradually upregulated from
the mature B cell stage to the plasma cell (13), the expression
of c-myc is progressively turned off (18). During this transi-
tion phase, c-myc controls both proliferation and apoptosis
(19), depending on signals provided by cytokines (20). Thus,
it is likely that Blimp-1 is a component of a regulatory com-
plex that controls the differentiation and apoptosis of acti-
vated B cells. In this work, we have identified an apparent
temporal window within which Blimp-1 causes apoptosis
as opposed to maturation. In particular, we have found that
ectopic expression of Blimp-1 in the immature WEHI-231,
mature L10A, and partially activated mature BCL1 5B1b cell
line, but not in activated 3B3 cells, results in extensive apop-
totic death. We have also identified an effector domain re-
sponsible for the induction of the apoptotic effect as being
mainly composed of a 69-amino acid (aa) stretch that en-
compasses most of its proline-rich domain. We suggest that
Blimp-1 may be a key participant of a regulatory checkpoint
that functions to promote fully activated B cells to terminal
differentiation and to eliminate partially activated B cells that
become arrested along the differentiation pathway.
 
Materials and Methods
 
Cell Lines and Cultures
 
BCL1 3B3 (ATCC CRL 1669) cells were purchased from the
American Type Culture Collection (Rockville, MD) and grown
as previously described (21). BCL1 5B1b cells were provided by
Dr. Samuel Strober (Stanford University) and were grown as pre-
viously described (22), except for lowering the concentration of
FCS to 10%. Where indicated, IL-2 and IL-5 (10% supernatants
from respective IL-2– and IL-5–producing cell lines; reference
23) were added. 18-81 cells were obtained from Dr. Matthias
Wabl (UCSF, San Francisco, CA; reference 24), and WEHI 231
1/8 cells from Dr. Noel Warner (Becton Dickinson, San Jose,
CA; reference 25). L10A (26) and BAL-17.7.1 (27) cells were a
gift of Dr. Richard Asofsky (NIAID, Bethesda, MD). The COS-7
(ATCC CRL 1651) cells were obtained from the American Type
Culture Collection (28). Human embryo epithelial cells 293T
were provided by Dr. Gary Nolan (Stanford University) and were
grown as previously described (29).
 
Blimp-1 Truncations
 
Blimp-1 
 
D
 
C
 
9
 
.
 
The Blimp-1 open reading frame (ORF) was
subcloned into the EcoRI site of the pyDF30 vector (provided by
Stephen Ho and Jerry Crabtree, Stanford University), a derivative
of the pcD-SR
 
a 
 
expression vector (30) that contains a sequence
encoding for a flu antigen (FLAG) octapeptide (31) located 3
 
9
 
from the multiple cloning site. The last 112 aa of Blimp-1 were
removed by using a unique Bsp120I site.
 
Blimp-1 
 
D
 
Proline.
 
The region encoding for aa 381–450 of
Blimp-1 was removed by using the unique AflII and SplI restric-
tion sites in the pyDF30/Blimp-1 vector. The ends of the restric-
tion were blunted and religated, resulting with the generation of
an in-frame truncation of 69 aa in Blimp-1 proline-rich domain.
 
Blimp-1 
 
D
 
N
 
9
 
.
 
The XbaI–MspI fragment of the pyDF30/
Blimp1 that contains the entire Blimp-1 ORF and flanking se-
quences was subcloned into the same sites of the pEJM1 vector.
This vector was derived from the pSH160s/NFAT vector (pro-
vided by Stephen Ho and Jerry Crabtree), and contains a se-
quence encoding for a FLAG octapeptide followed by three re-
peats of the SV40 large T antigen nuclear localization signals
(NLS) (32). The first 179 aa of Blimp-1’s ORF were removed by
digesting the pyDF30/Blimp-1 vector with XbaI and XcmI. The
resulting construct encoding for an N
 
9
 
 truncated version of
Blimp-1 was fused to three repeats of the SV40 NLS and a FLAG
tag. This manipulation prevented the deletion of any potential
NLS sequences from Blimp-1 NH
 
2
 
 terminus required for its
translocation.
 
Blimp-1 NZ.
 
Keller and Maniatis (33) found that the 65 aa
that located NH
 
2
 
 terminal to the zinc fingers were important for
protein stability. Therefore, we included the equivalent region of
Blimp-1 together with its zinc fingers (hereafter named the NZ
domain) in the “minimal Blimp-1 protein”. Nucleotides 1615–
2289 of the Blimp-1 ORF (13) were previously cloned into a
pET24d(
 
1
 
) expression vector (Novagene, Madison, WI). In
brief, the sequence was amplified for 15 cycles with a high fidelity
PCR enzyme (the ULTIMA
 
Ô
 
DNA polymerase; Roche Molec-
ular Systems, Inc., Branchburg, NJ) and cloned between the
BamHI and HinDIII sites of the vector pET24d(
 
1
 
). The NZ
fragment was generated from HindIII digestion of the Blimp-1
containing pET24d(
 
1
 
) vector followed by blunting and was then
cloned into the EcoRI site of pEJM1 vector.
 
GFP Expression Vector
 
The green fluorescent protein (GFP) expression vector was
based on the pG310 expression vector provided by Dr. Edward
Mocarski (Stanford University). In brief, the promoter and en-
hancer of ie1, exon 1, and intron 1 of CMV (
 
2
 
1022 to 
 
1
 
947)
were inserted between the XbaI and HinDIII sites of the
polylinker of pGEM-2 (Promega, Madison, WI). A polyadenyla-
tion signal from the ie1 gene was inserted between the BamHI
and ClaI sites (
 
1
 
2756 to 
 
1
 
2916). Finally, the NheI–XbaI portion
of the pG310 was removed. A vector containing a mutated GFP
ORF (provided by Dr. Stanley Falkow, Stanford University),
which produces an enhanced fluorescent protein (34), was blunt-
ended and ligated into the EcoRV site of LITMUS
 
Ô
 
 28 (New
England Biolabs, Beverly, MA). An EcoRI–BamHI fragment that
contained the GFP insert was cloned into the same sites of
pG310. The resulting GFP expression vector was named pTYG-1.
 
Transient Transfections
 
All cells (except 293T) were transfected by electroporation ac-
cording to Chu et al. (35). BCL1 and COS-7 cells were sus-
pended at 2.5 
 
3 
 
10
 
7
 
/ml in DMEM plus 10% FCS. Ten million
cells (400 
 
m
 
l) were placed in a 0.4-cm electrode gap gene pulser
cuvette (Bio-Rad, Hercules, CA). After the addition of 10 
 
m
 
g of
the vector(s), the samples were gently shaken and subjected to
electroporation in a GENEPULSER
 
Ô
 
 apparatus (Bio-Rad) set
to 960 
 
m
 
F and 230 mV for COS-7 cells or 250 mV for BCL1
5B1b and 3B3 cells. The cells were then incubated for 10 min at
room temperature and resuspended in 10 ml of complete media.
Approximately 10% of the cells were plated on a coverslip placed
in a 6-well tissue culture dish and used for immunostaining 24 h
after transfection. The rest of the cells were plated in a 10-cm dish
and incubated for 48 h before lysis and Western blot analysis. 18-81
cells were suspended at 1.7 
 
3 
 
10
 
7
 
/ml in RPMI
 
 
 
plus
 
 
 
10% FCS.
Five million cells (300 
 
m
 
l) were subjected to electroporation set
to 960 
 
m
 
F and 240 mV as described above. The transfected cells 
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were cultured in 10 ml RPMI media for 18 h. WEHI 231 1/8
and L10A cells were suspended at 2 
 
3 
 
10
 
7
 
/ml DMEM plus 20%
FCS. Five million cells (250 
 
m
 
l) were incubated for 10 min on ice
with the vector(s) before being electroporated (960 
 
m
 
F, 240 mV).
After electroporation, the cells were kept on ice for 5 min, and
then 1.75 ml DMEM plus 20% FCS were added and the suspen-
sions were kept at room temperature for 10 min. The transfected
cells were transferred to a 6-well petri dish and cultured for 18 h.
293T cells were transfected by the calcium phosphate method ac-
cording to Pear et al. (36). In brief, 7.5 
 
3 
 
10
 
6
 
 cells were transfected
with 5 
 
m
 
g of truncated Blimp-1 expression vectors. 48 h after
transfection the cells were harvested and nuclear extracts were
prepared.
 
In situ TUNEL Assay
 
The TUNEL (TdT-mediated dUTP nick end labeling) assay
was performed with an in situ cell death detection kit following the
manufacturer’s instruction (Boehringer Mannheim GmbH, Mann-
heim, Germany). In brief, DP1/GFP double transfected and GFP
transfected control 3B3 and 5B1b cells were sorted by FACS
 
Ò
 
(Becton Dickinson) and incubated for an additional 48 h. The cells
were then centrifuged onto glass slides using a Shandon cytospin
(Pittsburgh, PA), air dried, and fixed for 30 min in 4% paraformalde-
hyde diluted in PBS (pH 7.4). After permeabilization with 0.1%
Triton X-100 diluted in 0.1% sodium citrate, the cells were labeled
with 50 
 
m
 
l of the TUNEL reaction mixture for 60 min at 37
 
8
 
C,
washed, and incubated for 30 min with 50 
 
m
 
l of converter-alkaline
phosphatase. The slides were rinsed and incubated for 10 min at
room temperature with 100 
 
m
 
l of Fast Red TR/Naphthol AS-MX
solution (Sigma Chemical Co., St. Louis, MO).
 
Immunostaining
 
pEJM1/NZ transfected cells were harvested 24 h after plating,
fixed with 4% paraformaldehyde, and permeabilized with 0.1%
Triton X-100 diluted in PBS. The cells were then stained for 1 h
with a mixture of 1% BSA, 2% normal rat serum, and a 1:1,000
dilution of anti-FLAG
 
Ò
 
 M2 antibody (Eastman Kodak Co.,
Rochester, NY). Cells were then washed with PBS and stained
with a 1:1,000 dilution of a biotinylated goat anti–mouse anti-
body (PharMingen, San Diego, CA) diluted in 1% BSA solution
in PBS. The slides were washed again with PBS and stained with
1% BSA and a 1:1,000 dilution of FITC-conjugated avidin di-
luted in 1% BSA solution in PBS. The cover slips were mounted
on slides with 10 
 
m
 
l of VECTASHIELD
 
Ò
 
 (Vector Labs., Inc.,
Burlingame, CA), fixed with nail polish, and examined under a
fluorescence microscope.
 
FACS
 
Ò
 
 Analysis and Cell Sorting
 
Cells were stained with mAbs for 30 min on ice in 50 
 
m
 
l of
PBS supplemented with 5% FCS (FACS buffer). The stained cells
were washed twice in FACS buffer, then resuspended in 200 
 
m
 
l
of buffer and analyzed on a FACScan
 
Ò
 
 with the FACSDesk soft-
ware (Beckman Center Shared FACS
 
Ò
 
 Facility, Stanford Univer-
sity). The antibodies used for the staining were the monoclonal
6A5.1 anti-BCL1 idiotype (gift of Ellen Vitetta, Southwestern
Medical Center, Dallas, TX), FITC-conjugated anti-IgD, PE-
conjugated anti–B7-2, FITC-conjugated anti-CD40, and bioti-
nylated anti–Syndecan-1 (PharMingen), and biotinylated anti-
IgM (Sigma Chemical Co.). Biotinylated antibodies were used as
a second step with either PE- or FITC-conjugated avidin
(PharMingen). Dead cells were excluded in each analysis by pro-
pidium iodide (PI) staining (37). GFP
 
1
 
/PI
 
2
 
 transfected 5B1b cells
were sorted 15–24 h after transfection using a preset compensa-
tion of the GFP for the PI channel. Cells were sorted into RPMI
media, washed once with media, and cultured with or without
stimuli for an additional 48 h.
 
Electromobility Shift Assay
 
293T cells transfected with truncated Blimp-1 mutants were
used to prepare nuclear extracts (38). In brief, cells were lysed in
0.5% NP-40, 30% sucrose, 25 mM Tris-HCl, pH 7.5, 25 mM
KCl, and 7.5 mM MgCl
 
2
 
 supplemented with proteinase inhibi-
tors (leupeptin, pepstatin, PMSF, and aprotinin). The nuclei were
spun and rinsed with RSB (10 mM NaCl, 10 mM Tris-HCl, pH
7.5, 10 mM MgCl
 
2
 
), and nuclear proteins were extracted. Nuclei
were resuspended first in 200 mM NaCl, 50 mM Tris-HCl, 0.2 mM
EDTA, 0.2 mM EGTA, 2 mM MgCl
 
2
 
, 0.5 mM dithiothreitol
(DTT), 5% glycerol, and protease inhibitors. Subsequently, an
equal volume of buffer composed of 600 mM NaCl, 50 mM
Tris-HCl, 0.2 mM EDTA, 0.2 mM EGTA, 2 mM MgCl
 
2
 
, 0.5 mM
DTT, 5% glycerol, and protease inhibitors was added. The nu-
clear protein was extracted with rotation at 4
 
8
 
C for 30 min and
spun for 60 min at 100,000 
 
g
 
. The protein concentration was de-
termined using a Bradford assay. 5 
 
m
 
g of each nuclear extract was
used for EMSA (electromobility shift assay) (38). In brief, the ex-
tracts were mixed with 10
 
5
 
 cpm of 
 
32
 
P–end-labeled PRFI
(CGCGTACAGAAAGGAAAGGACTAG) (17) or PRDI (GT-
GAAAGGGAGAAGTGAAAGTGGGAAATTCC) (14) probe,
3 
 
m
 
g poly (dI-dC) in binding buffer (10 mM Tris-HCl, pH 7.5, 1
mM DTT, 1 mM EDTA, 5% glycerol, and 10 
 
m
 
M ZnSO
 
4
 
). Af-
ter 30 min incubation at room temperature, the reactions were
subjected to electrophoresis on a 6% polyacrylamide gel at 180V
for 1.5–2 h. Competitors (100
 
3
 
) were incubated for 30 min be-
fore the addition of the labeled probe. After separation, the gel
was fixed, dried, and exposed for 2 h to a BIOMAX MS film at
 
2
 
80
 
8
 
C (Eastman Kodak Co.).
 
ELISA
 
The amount of IgM in the supernatants was quantitated using
a sandwich ELISA (39). In brief, 50 
 
m
 
l of a 10 
 
m
 
g/ml solution of
goat anti–mouse IgM (Sigma Chemical Co.) was plated on an
IMMULON
 
Ò
 
 4 plate and the plate was incubated for 2 h at
37
 
8
 
C. Excessive antibody solution was removed and 200 
 
m
 
l of 5%
BSA in PBS was added to each well and incubated overnight at
4
 
8
 
C. The plate was washed three times with 200 
 
m
 
l of 1% BSA/
PBS, and incubated for 2 h at 30
 
8
 
C with 200 
 
m
 
l of decreasing di-
lutions of culture supernatants that had been centrifuged at 1,000 
 
g
 
to remove remaining cell debris. A standard curve was deter-
mined with different concentrations of mouse anti-MOPC104e
IgM (Sigma Chemical Co.). The plates were washed three times
with 1% BSA/PBS and incubated for 2 h with 50 
 
m
 
l of 1:14,000
dilution of alkaline phosphatase–conjugated goat–anti mouse IgM
(Sigma Chemical Co.). After three washes the plates were incu-
bated with 50 
 
m
 
l of SIGMA 104
 
Ò
 
 phosphatase substrate (Sigma
Chemical Co.) diluted in zinc-buffer (100 mM Glycine NaOH,
pH 10.0, 1 mM ZnSO
 
4
 
, 1 mM MgCl
 
2
 
) until a visible color
change was seen. The plates were analyzed using a 96-well plate
reader and VMAX software according to the manufacturer’s rec-
ommendation (Molecular Devices, Menlo Park, CA).
 
Cell Cycle Analysis
 
Cell cycle analysis was performed according to a modified pro-
tocol for PI staining of cell nuclei (40). In brief, cell pellets were 
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Figure 1. Characterization of BCL1
5B1b and CW13.20-3B3 sublines.
Morphology: the BCL1 5B1b (A)
and CW13.20-3B3 (D) sublines
were photographed at the log phase
at 3320. Expression of cell surface
markers: 106 cells were stained for 30
min on ice with different combina-
tions of antibodies; anti-IgD and
anti-IgM (B and E) and anti-CD25
and anti–B7-2 (C and F). The cells
were analyzed on a FACScanÒ with
the FACSDesk software. Cell cycle
analysis: 106 BCL1 CW13.20-3B3
(a) and BCL1 5B1b (b) cells were permeabilized and the nuclei stained with PI.
The distribution of the nuclei size between the different phases of the cell cycle
was measured using a FACScanÒ device and the data were analyzed using the
ModFit LTÔ algorithm. The percentage of the cells at the different phases of the
cell cycle are indicated on the top of each phase.
resuspended in 100 ml 85.5 mg/ml sucrose, 11.7 mg/ml sodium
citrate, and 5% DMSO, pH 7.6. The cells were trypsinized and
permeabilized by adding 900 ml of 0.003% trypsin diluted in SS
buffer (0.1% sodium citrate, 0.1% NP-40, 1.5 mM spermine-
4HCl in 50 mM Tris base [pH 7.6]) for 20 min. The trypsin and
cell RNA were inhibited and degraded by adding 0.05% trypsin
inhibitor and 0.01% RNase diluted in SS buffer for 20 min at
room temperature. Finally, the cells were stained with 0.01% PI
and 3.3 mM spermine-4HCl in SS buffer for 20 min. The cells
were then analyzed on a FACScanÒ or an EPICSÒ ELITE fluo-
rescense-activated cell sorter (Coulter, Miami, FL) by adjusting
the voltage of the instrument to distinguish between the different
phases of the cell cycle and data were collected using the FACS-
Desk software. The collected data were further analyzed by
ModFitÒ software (Verity Software House, Inc., Topsham, ME)
and the distribution of the cells between the different phases of
the cell cycle and apoptosis percentages was adjusted to fit the
software developer’s suggestions.
Results
The 5B1b and 3B3 Sublines Express Surface Markers that
Represent Closely Related but Distinct Stages of B Cell Matura-
tion. The mature leukemic 3B3 B cell subline was derived
from the leukemia-lymphoma BCL1 5B1b (41) and dis-
plays a lower spontaneous secretion level of IgM as com-
pared with the parental line (42). Blackman et al. (21)
showed that this low level of secretion is due to deficient J
chain expression and suggested that these cells are partially
activated due to the lack of a second signaling event for
complete maturation. Although the different BCL1 sub-
lines were cloned over a decade ago, the maturation differ-
ences between them have not been characterized exten-
sively. When the 5B1b and 3B3 sublines were stained with
an antiidiotypic mAb, 6A5.1. (43), both lines were strongly
positive (data not shown), confirming that they were deriv-
atives of the same clone. However, they differed in a num-
ber of morphological, biochemical, and developmental pa-
rameters. The 3B3 line exhibited a more regular and
rounded morphology (Fig. 1 D) with a slow growth rate.519 Messika et al.
3B3, but Not 5B1b Cells, Differentiate into Centrocyte-like
Cells after IL-2 and IL-5 Stimulation. Differentiation of the
3B3 cells into IgM secreting cells was characterized by their
ability to secrete IgM and upregulate J chain expression
(44). We followed the changes in the size and expression of
several surface expression markers for 72 h after stimulation
with IL-2/IL-5. Before cytokine treatment, the partially
activated 5B1b cells were IAd BrightCD19BrightCD44Bright
SyndecanNeg (references 10, 45; Fig. 2, B and C), with a
cell size peaking at 240 afU (arbitrary fluorescence units)
and cell granularity at 160 afU (Fig. 2 A). After 72 h of
IL-2/IL-5 stimulation, the cell size increased slightly and
peaked at 280 afU, and granularity increased to 185 afU
(Fig. 2 D). This change was accompanied by a 100-fold
Figure 2. Kinetics of BCL1 CW13.20-3B3 (A–F) and BCL1 5B1b (G–L) differentiation after IL-2 and IL-5 stimulation. The two BCL1 sublines were
plated at 106/ml and stimulated with 10% vol/vol IL-2 and IL-5 supernatants for 72 h. Stimulated (D–F and J–L) and resting (A–C and G–I) cells were
then collected and subjected to staining with two combinations of markers: anti-IAd and anti-CD19 (B, E, H, and K); and anti-CD44 and anti–Synde-
can-1 (C, F, I, and L). The cell size and granularity (A, D, G, and J) and expression levels of the different markers were measured by a FACScanÒ device
and the data were processed using the FACSDesk software. The expression level of the cell surface markers of BCL1 CW13.20-3B3 at 72 h refers to the
population marked with a square box in the cell size/granularity display (J) at the top plot. The analysis of the expression of the markers at the other time
points refer to the entire cell population.
Cell cycle distribution of the line was characteristic of rela-
tively differentiated cells, with .50% cells in the G0/G1-
phase (Fig. 1 b). The 5B1b cells, on the other hand, were
larger and more dendritic (Fig. 1 A), and had a majority
(54.4%) of cells in the S-phase of the cell cycle (Fig. 1 a).
In addition to these differences in morphology and cell
cycle distribution, the expression of several cell surface mark-
ers also differed. 40–50% of the 5B1b line exhibited a rela-
tively nonactivated phenotype (IgMBrightIgDBrightCD86Dull)
(Fig. 1, B and C), whereas the 3B3 line appeared to be fully
activated (IgMBrightIgDDullCD86Bright) (Fig. 1, E and F).
This indicates that although both sublines originated from
the same mature B cell clone, they differed from each other
in their activation states.520 Induction of Apoptosis by Blimp-1
downregulation of IAd expression on the cell surface of
z30% of the cells (Fig. 2 E). There were no noticeable
changes in the cell surface expression of CD19, CD44, and
Syndecan-1 (Fig. 2 F).
In contrast to these relatively minor changes in the 5B1b
cells, the 3B3 line responded much more dramatically to
IL-2/IL-5 stimulation. In particular, a small percentage of
the resting 3B3 cells were IAd DullCD44DullSyndecan1Bright
and expressed z50% less CD19 (Fig. 2, H and I) than
5B1b. After IL-2/IL-5 stimulation, this minor population
gradually became the dominant phenotype (Fig. 2, K and
L) concomitant with a substantial decrease in cell size from
a peak at 220 afU to a peak at 100 afU (Fig. 2, G and J).
These changes suggest that the 3B3 cells differentiated
from an activated mature phase to a centrocyte-like cell af-
ter IL-2/IL-5 stimulation.
Blimp-1 Induces Apoptosis in Multiple B Cell Lines but Not in
the BCL1 3B3. Lin et al. (17) demonstrated that Blimp-1
induces apoptosis in the 18-81 pre–B cell line. This effect
was shown to correlate with the downregulation of c-myc
expression by Blimp-1. Suppression of c-myc was also re-
ported to induce apoptosis in the immature B cell line WEHI-
231 (46). These data suggest that Blimp-1 may induce an
apoptotic response at several stages of the B cell develop-
ment. We therefore compared the effect of the transfection
of Blimp-1 into the pre–B 18-81, immature WEHI-231,
mature L10A, and the BAL17 cell lines. The results showed
that by as early as 18 h after transfection, 10–80 mg of
Blimp-1 induced 11–38% apoptosis in WEHI-231 in a
dose-dependent manner (Fig. 3, a–d). A similar effect was
also found in the L10A and the 18-81 cell lines (Fig. 3 e
and reference 17). In BAL17, Blimp-1 transfection induced
apoptosis but the effect was not dose dependent (Fig. 3 e).
We also compared the long-term effect of the transfection
of a low amount of Blimp-1 into 5B1b and 3B3 cells. Both
sublines were transfected with 10 mg of Blimp-1 and 10 mg
of GFP constructs, and selected for GFP expression by
FACSÒ after a 15 h incubation. Approximately 5–20% of
the cells were positive for GFP, and these were cultured for
an additional 72 h and then centrifuged onto slides for in
situ TUNEL assay. Apoptosis as determined by the intense
nuclear TUNEL staining and condensed nuclear morphol-
ogy were clearly evident in Blimp-1–transfected 5B1b (Fig.
4 B) but not 3B3 (Fig. 4 A).
The Blimp-1 “Death Domain” Is Located within the Proline-
rich Domain. To identify the domain(s) in Blimp-1 that
was involved in the induction of apoptosis, we examined
the proapoptotic ability of four truncation mutants in
WEHI-231 cells. In the DN9 truncation mutant, the N9
acidic domain (aa 71–87) and the first 49 aa of the PRD1-
BF1-RIZ homology (PR) domain (aa 131–179) were re-
moved. To compensate for the possible depletion of a nec-
essary NLS, three SV40 NLS were introduced 59 to the
truncated ORF. The results show that this truncation had
Figure 3. Blimp-1 induces apoptosis in L10A, BAL17, WEHI-231, and 18-81 cells. L10A,WEHI-231, and 18-81 cells were transiently transfected
with increasing amounts of the DP1 (Blimp-1) expression vector. After 18 h of recovery at 378C, the cells were permeabilized and the nuclei stained with
PI. The distribution of the nuclei size between the different phases of the cell cycle was measured using an EPICSÒ Elite fluorescense-activated cell sorter
device and the data were analyzed using the ModFITÔ algorithm. Cell cycle analysis of WEHI-231 cells after the transfection of 10 mg (b), 40 mg (c), 80
mg (d), and mock-transfected cells (a). The percentage of apoptotic cells is indicated on the top of each transfection. (e) Comparison of apoptotic effect of
Blimp-1 on WEHI-231, 18-81, BAL17, and L10A cell lines. Cells were transfected with 40 and 80 mg of Blimp-1 and apoptosis was analyzed by cell cy-
cle distribution as described above. The data represent the mean of three experiments (6 SEM).521 Messika et al.
minimal effect on the ability of Blimp-1 to induce apoptosis
in WEHI-231 cells (Fig. 4). On the other hand, the depletion
of the C9 acidic domain (aa 752–810) had a modest effect on
the ability of Blimp-1 to induce apoptosis in WEHI-231 cells
(Fig. 5 B). The transfection of this DC9 truncation mutant re-
duced the apoptotic ability of Blimp-1 by z20%. The most
significant effect on the ability of Blimp-1 to kill WEHI-
231 cells was noticed when a portion of the proline-rich
domain was removed (aa 381–450). The truncation of
this domain reduced the apoptotic ability of Blimp-1 on
WEHI-231 by 82%. A comparable loss of the proapoptotic
activity was observed when most of the putative effector
domains of Blimp-1 were removed, as in the NZ construct.
The loss of the proapoptotic activity of NZ construct was
not due to its inability to translocate into the nuclei because
the fusion of the SV40 NLS to the NZ fragment enables
proper nuclear translocation of the protein. In situ staining
of transfectants with the M2 anti-FLAG antibodies showed
that the protein clearly localized to the nucleus (Fig. 5 D).
Furthermore, the deletion of a major portion of the pro-
line-rich domain in the Dproline construct did not alter the
DNA binding ability of the recombinant protein to the
b-interferon (PRDI) or the c-myc (PRFI) elements (Fig.
5 C). A similar pattern was observed when most Blimp-1
effector domains were removed in the NZ truncation mu-
tant (results not shown). These results indicate that the loss
of the proapoptotic function in the Dproline and the NZ
recombinant proteins was probably due to the inability of
these truncated proteins to interact with other nuclear fac-
tors that are required for the induction of apoptosis.
Blimp-1 Is Involved in the Induction of Apoptosis and Partial
Differentiation of 5B1b Cells. To examine whether or not
the NZ recombinant protein was able to block the induc-
tion of apoptosis in B cells and the development of Blimp-
1–induced changes, such as IgM secretion and blasting, we
cotransfected 5B1b cells with different combinations of
Blimp-1 and/or the NZ construct and with the GFP ex-
pression vector as a selection marker. 24 h after transfec-
tion, the viable GFP1 5B1b cells were sorted and incubated
for an additional 48 h with or without IL-2/IL-5 stimula-
tion. At the end of the cell culture, the level of IgM, per-
centage of blasting (cells gated on forward scatter between
Figure 4. Blimp-1 induces apoptosis in BCL1 5B1b but not in BCL1 CW13.20-3B3 cells. BCL1 5B1b and BCL1 3B3 cells were transiently trans-
fected either with the DP-1 (Blimp-1) vector and the pTYG-1 (GFP) vectors (A and B) or with the GFP vector alone as a negative control (C and D).
GFP1/PI2 cells were sorted 15 h after transfection and incubated for an additional 48 h. The cells were then cytospun on slides coated with poly-l-lysine,
fixed with 4% paraformaldehyde, permeabilized, and stained for in situ TUNEL assay following the manufacturer’s instructions. The stained cells were
developed with Fast Red and photographed at 3320.522 Induction of Apoptosis by Blimp-1
160 and 250), and percentage of dying cells (determined by
GFP1/PI1) were examined. The results showed that the
transfection of NZ suppressed the low spontaneous cell
death of 5B1b. The ectopic overexpression of Blimp-1 in-
duced a robust apoptotic response. This response could be
suppressed in cells cotransfected with the NZ and Blimp-1
expression vectors (Fig. 6 B). Although insufficient for driv-
ing the 5B1b cells to a fully differentiated phenotype (Fig. 2),
IL-2/IL-5 treatment induced an increase in IgM secretion
and in the percentage of blasts in these cells (Fig. 6 A).
Ectopic expression of the NZ protein alone resulted in an
approximately twofold reduction in both IgM secretion and
the percentage of blasting cells in response to IL stimulation
(Fig. 6 A). However, IL-2/IL-5 treatment of NZ transfected
cells produced an apoptotic response that was almost seven-
fold higher than control 5B1b cells. On the other hand,
Blimp-1 transfection-induced apoptosis of these cells was
slightly reduced by IL-2/IL-5 treatment (Fig. 6 B). These
results suggest that the blasting and IgM secretion effects trig-
gered by IL-2/IL-5 in 5B1b might be dependent on an ade-
quate expression level of Blimp-1. Nevertheless, these effects
did not seem to be connected with the apoptotic ability of
Blimp-1. Therefore, it seems that in partially activated B
cells, Blimp-1 may have a balanced effect between the in-
duction of apoptosis and the induction of maturation. One
possible explanation for this effect is that the contribution of
Blimp-1 to either pathway requires the coexpression of
stage-specific factors that would shift Blimp-1 function from
induction of apoptosis to promotion of differentiation.
Discussion
Blimp-1 was originally shown to regulate the expression
of structural genes (J chain and Syndecan-1) during the dif-
Figure 5. Construction, expression, and cellular localization of NZ, a
dominant negative form of Blimp-1. (A) Scheme of the truncated pro-
teins. Lane 1, full-length Blimp-1 fused to a FLAG tag; lane 2, DN9; lane
3, Dproline; lane 4, DC9; lane 5, NZ. (B) Apoptotic efficiency of WEHI-
231 cells after transient transfection with the truncated Blimp-1 proteins.
WEHI-231 cells were transiently transfected with 70 mg of the expression
vectors expressing the truncated forms of Blimp-1. Mock transfected cells
were transfected with 70 mg of the TYG-1 vector. After 18 h of recovery,
the cells were harvested and apoptosis was determined by cell cycle analy-
sis. Mean percentage of apoptotic cells was deduced from the cell cycle
histograms of three experiments (6 SEM), using the ModFit LTÔ soft-
ware according to the software developer. (C) EMSA (electromobility
shift assay) analysis of Blimp-1 and Dproline. 5 mg of Blimp-1 and Dpro-
line were transfected into 293T cells and nuclear extracts were prepared.
5 mg of the nuclear extracts were used in each gel shift reaction and
mixed with labeled PRDI or PRFI probes. PRDI binding competition
assays were performed with an excess of 100-fold unlabeled PRDI probe.
The reactions were run on a 6% polyacrylamide gel and exposed to an
X-ray film for 2 h. (D) FLAG tagged NLS-NZ dominant negative pro-
tein localize to the cell nuclei (original magnification: 3630). COS-7 cells
were transfected transiently with the pEJM1-NZ construct and platted for
15 h on glass coverslip. The adherent cells were fixed with 4% parafor-
maldehyde and permeabilized with 0.1% Triton X-100/PBS. The cells
were then stained with an anti-FLAG M2 antibody (Eastman Kodak
Co.), and a sandwich of biotinylated goat anti–mouse antibody (Phar-
Mingen) and FITC-conjugated avidin (Amersham International, Little
Chalfont, Buckinghamshire, UK). (D) Phase contrast view of the trans-
fected cells. Three nuclei are visible on the left cell and two on the right.
(C) FITC view of the same cells. The nuclei of both cells are stained at
different intensities with the anti-FLAG antibody. No staining is visible in
the cytoplasmic compartment of the cells.523 Messika et al.
ferentiation of mature B lymphocytes into plasma cells (13).
Recently, it has been found that the expression of Blimp-1
in pre–B cells triggers an apoptotic response that appears to
be mediated by the downregulation of c-myc expression
(17). Here we report that Blimp-1 can induce apoptosis
across a broad range of immature and mature B cell lym-
phoma lines and can only promote differentiation in fully
activated B cells. We also have identified the functional do-
main required for the induction of apoptosis and anticipate
that Blimp-1 functions may depend upon the stage-specific
expression of a cofactor.
The developmental stages represented by the 5B1b and
3B3 sublines appear to define a temporal window of B cell
differentiation within which the function of Blimp-1 shifts.
Partially activated 5B1b cells are impaired in their responses
to IL-2/IL-5 stimulation and arrested at the centroblast
stage. On the other hand, fully activated 3B3 cells respond
to IL-2/IL-5 stimulation and differentiate into centroblast
and, later, centrocyte-like cells (Fig. 2). The transfection of
5B1b cells with the NZ dominant negative suppresses
blasting and IgM secretion induced by IL-2/IL-5 treatment
(Fig. 6), thus indicating that Blimp-1 is an essential compo-
nent in IL-2/IL-5 signaling during B cell maturation. In
contrast to the antidifferentiation effect of NZ, overexpres-
sion of Blimp-1 in 5B1b but not in 3B3 cells results in
marked apoptotic death that can be suppressed by the NZ
dominant negative. This, in turn, indicates that the Blimp-
1–mediated apoptotic machinery is still functional in the
5B1b cells. Similarly, the transfection of Blimp-1 in earlier
stages of the B cell development, such as the pre–B (18-
81), immature B (WEHI-231) and mature B (L10A) cell
stages induces an apoptotic response. This effect is mainly
dependent on a 69-aa region within the proline-rich do-
main (Fig. 5). It is conceivable that the binding of an addi-
tional factor to this domain is required to elicit a response.
For example, Blimp-1 may interact in vitro with YY1, a
positive regulator of c-myc (17), whose expression plays an
important role in controlling the cell fate. Since the down-
regulation of c-myc was shown to be involved in the in-
duction of apoptosis in both 18-81 (17) and WEHI-231
(46), its suppression by Blimp-1 is anticipated to play a role
in the elimination of partially activated B cells. However, it
appears that other genes that are involved in the regulation
of the cell cycle may be targeted by Blimp-1.
The PR domain (aa 131-231) (16) was suggested to
modulate the repressor ability of RIZ (47). Our results
show that the deletion of 50% of this domain in the DN9
truncated protein had no significant effect on the ability of
this protein to induce apoptosis in WEHI-231 cells. There-
fore, the integrity of the PR domain may be unnecessary
for the induction of apoptosis. In fact, the truncation of ei-
ther the N9 or C9 acidic domains had only a minor effect
on the apoptotic ability of Blimp-1 (Fig. 5 B).
Given that Blimp-1 is able to exert such different effects
in closely related cells, the question arises as to how this is
accomplished. One possible explanation is that different
combinations of the zinc finger motifs may recognize dis-
tinct gene targets. A mechanism of this type was recently
shown in the case of NeP1/CTCF, an 11–zinc finger pro-
tein that uses different combination of its zinc fingers to
bind to either the c-myc gene or the lysozyme silencer, F1
(48). The partial use of Blimp-1 zinc fingers for the recog-
nition of potential targets was demonstrated in the work of
Keller and Maniatis (32). In that report the authors show
that two out of the five PRDI-BF1 zinc fingers (and a
stretch of 65 aa located N9 to these fingers) are sufficient for
its binding to the PRDI element. Recently, we have found
that the binding of NZ to the PRF1 element, but not to
the PRD1 element, is sensitive to posttranslational modifi-
cations or conformational changes (Chi, J.-T., and E.J.
Messika, unpublished results). Thus, Blimp-1 may be mod-
ulated to switch specificity to different targets due to inter-
actions with stage-specific proteins, using different combi-
nations of its zinc fingers, as the cell matures.
In summary, we propose that Blimp-1 may be part of a
“gate keeper” mechanism in the differentiation process, as
its upregulation causes apoptosis of immature or partially
stimulated B cells. This may constitute an important selec-
tion mechanism to eliminate self-reactive B cells that have
escaped earlier negative selection mechanisms or have been
inappropriately (and partially) activated.
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